Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements

J Psychiatr Res. 2010 May;44(7):429-33. doi: 10.1016/j.jpsychires.2009.10.012. Epub 2009 Nov 22.


Several studies show that calcium-binding protein S100B is increased in schizophrenia and may be involved in the pathogenesis of tardive dyskinesia (TD). We therefore compared serum S100B levels in normal controls (n=60), schizophrenic patients with (n=32) and without TD (n=50). Assessments included the abnormal involuntary movement scale (AIMS) and the positive and negative syndrome scale (PANSS). Serum S100B levels were measured by enzyme-linked immunosorbent assay (ELISA). The results indicated that patients with TD had higher serum S100B levels than normals and those without TD. Serum S100B levels were positively correlated with AIMS scores in patients with TD. These data suggest that increased S100B levels may be related to neuro-degeneration, associated with TD pathophysiology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Akathisia, Drug-Induced / blood*
  • Akathisia, Drug-Induced / complications*
  • Case-Control Studies
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nerve Growth Factors / blood*
  • Regression Analysis
  • S100 Calcium Binding Protein beta Subunit
  • S100 Proteins / blood*
  • Schizophrenia / blood*
  • Schizophrenia / complications*
  • Severity of Illness Index


  • Nerve Growth Factors
  • S100 Calcium Binding Protein beta Subunit
  • S100 Proteins
  • S100B protein, human